home / stock / mycof / mycof news

MYCOF News and Press, New Age Brands From 02/02/24

Stock Information
Company Name: New Age Brands
Stock Symbol: MYCOF
Market: OTC
Website: mydecine.com
Menu
MYCOF MYCOF Quote MYCOF Short MYCOF News MYCOF Articles MYCOF Message Board
Get MYCOF Alerts

News, Short Squeeze, Breakout and More Instantly...
MYCOF - Mydecine Innovations Group Announces Director Resignation

VANCOUVER, British Columbia, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE: 0NF0), a forefront biotechnology company dedicated to revolutionizing mental health and addiction treat...
MYCOF - InvestorNewsBreaks - Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces USPTO Issues Notice of Allowance for MYCO-005 Compound

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a forefront biotechnology company dedicated to revolutionizing mental health and addiction treatment, has received the issuance of a Notice of Allowance by the United States Patent and Trademark Office (“USPTO”). Accor...

MYCOF - Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound

VANCOUVER, British Columbia, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a forefront biotechnology company dedicated to revolutionising mental health and addiction treatm...

MYCOF - InvestorNewsBreaks - Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Updates Special Access Program

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder, has announced clarific...
MYCOF - Mydecine Announces Update Regarding the Special Access Program

DENVER, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental ...

MYCOF - InvestorNewsBreaks - Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Files Prospectus Supplement, Closes Share Subscription Agreements

Mydecine Innovations (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) , a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, has filed a shelf prospectus supplement to...

MYCOF - Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements

VANCOUVER, British Columbia, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment prot...
MYCOF - InvestorNewsBreaks - Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Reports on Company Progress in Q4 2023 Update

Mydecine Innovations (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) , a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, has released a fourth-quarter 2023 company...

MYCOF - Mydecine Provides Q4 2023 Business Update

VANCOUVER, British Columbia, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment pro...

MYCOF - Mydecine Innovations Group gearing up for human trials after completing Aquis listing

--News Direct-- Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) CEO Joshua Bartch speaks to Thomas Warner from Proactive London about the biotechnology company's ambitious goals in the psychedelic medicine sector. Bartch explains that Mydecine focuses on developing "second genera...
Previous 10 Next 10